Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending February 12, 2007. The report announces a change to the Board of Directors, specifically the appointment of Dr. Stephanie Burns as a Non-Executive Director with immediate effect.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a corporate governance announcement and does not contain financial performance data.
Material Changes
The primary material change is the addition of Dr. Stephanie Burns to the Board of Directors. Dr. Burns, previously the Chairman, President, and CEO of Dow Corning Corporation, brings expertise in organic chemistry and global business leadership. The Board has determined she is independent in accordance with the Combined Code on Corporate Governance.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of risks and contingencies. Management commentary is limited to Chairman Sir Christopher Gent's statement welcoming Dr. Burns for her scientific background and advocacy for science education.
Key Facts for Investor Verification
- Dr. Stephanie Burns has been appointed as an Independent Non-Executive Director effective February 12, 2007.
- Dr. Burns holds a Ph.D. in organic chemistry and previously served as CEO of Dow Corning Corporation.
- The updated Board and Committee membership lists reflect Dr. Burns' addition to the Board.
- This filing does not include financial results; investors should refer to Form 20-F or quarterly reports for financial data.